AAP
NAGE

Arax Advisory Partners’s Niagen Bioscience NAGE Stock Holding History

Arax Advisory Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47K Sell
773
-163
-17% -$661 ﹤0.01% 4773
2026
Q1 		$4.13K Buy
936
+933
+31,100% +$5.04K ﹤0.01% 2877
2025
Q4 		$19 Sell
3
-20,142
-100% -$140K ﹤0.01% 4025
2025
Q3 		$188K Buy
+20,145
New +$203K ﹤0.01% 1286

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Arax Advisory Partners's NAGE Position: Q2 2026 in Review

Arax Advisory Partners reduced its Niagen Bioscience (NAGE) stake by 17% in Q2 2026, selling an estimated $661 and leaving 773 shares worth $2.47K. The position accounts for ﹤0.01% of the portfolio, ranked #4773.

Arax Advisory Partners first reported a position in NAGE in Q3 2025 and has held it in 4 quarters since. The position peaked at $188K in Q3 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Arax Advisory Partners held 773 shares of Niagen Bioscience worth $2.47K as of Q2 2026.
  • Arax Advisory Partners sold 163 Niagen Bioscience shares in Q2 2026, an estimated $661.
  • Niagen Bioscience made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4773 holding.
  • Arax Advisory Partners first reported a position in Niagen Bioscience in Q3 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Niagen Bioscience position peaked at $188K in Q3 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.